In FY 2022-23, the company registered Revenue from Operations of Rs 51,397 million, compared to Rs 47,344 million in the previous year.
Bayer CropScience Limited announced its results for the financial year (FY) and quarter ended March 31, 2023. In FY 2022-23, the Company registered Revenue from Operations of Rs 51,397 million, compared to Rs 47,344 million in the previous year, registering an overall revenue growth of 9 per cent. Profit Before Exceptional Items & Tax stood at Rs 8,863 million, compared to Rs 7,883 million in the previous year, representing an increase of 12 per cent. Profit Before Tax (After Exceptional Items) increased by 17 per cent from Rs 8,468 million to Rs 9,901 million.
In Q4 of FY 2022-23, the Company registered Revenue from Operations of Rs 9,825 million, compared to Rs 9,633 million in the corresponding quarter of the previous year, delivering a growth of 2 per cent. Profit Before Exceptional Items & Tax for the quarter stood at Rs1,921 million, compared to Rs 1,895 million in the corresponding quarter of the previous year.
Commenting on the quarterly results, Simon-Thorsten Wiebusch, Executive Director, Bayer CropScience Limited said, “Our sales growth in Q4 continued to be driven by strong crop protection sales and consistent performance by our corn seeds business while overcoming some supply constraints faced during the quarter. Although our channel inventory continues to remain at healthy levels, we are witnessing a normalization of Roundup™ prices and availability.”
Speaking on the FY results, Simon Britsch, Chief Financial Officer, Bayer CropScience Limited said, “The steady performance of our crop protection and corn seeds portfolio helped us deliver 9 per cent growth in Revenue from Operations for the financial year. Though headwinds in the form of inflationary pressures led to higher operating expenses, we continued to invest in key initiatives to drive long-term growth. During the year, the company had an exceptional income of Rs 1,038 million arising from the sale of its Environmental Science Business in Q3 of FY 2022-23.”